Familial hypobetalipoproteinemia in pediatric patients with fatty liver: an under-recognized cause

Nurit Loberman Nachum1,2, Eyal Shteyer3,4, Hofit Cohen2,5

  • 1Pediatric Gastroenterology and Nutrition Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.

Insights

Familial hypobetalipoproteinemia (FHBL) is an important consideration in children with fatty liver, especially when other causes are not apparent. Genetic evaluation can identify FHBL in pediatric fatty liver cases.

Area of Science:

  • Pediatric Gastroenterology
  • Clinical Genetics
  • Hepatology

Background:

  • Fatty liver is a prevalent cause of chronic liver disease in children, frequently linked to metabolic dysfunction-associated steatotic liver disease (MASLD).
  • In lean or younger children, fatty liver may signal underlying genetic or metabolic disorders, including familial hypobetalipoproteinemia (FHBL).

Purpose of the Study:

  • To highlight the significance of considering familial hypobetalipoproteinemia (FHBL) in the diagnostic workup of children presenting with fatty liver.
  • To investigate the clinical characteristics and genetic basis of FHBL in a cohort of pediatric patients with fatty liver.

Main Methods:

  • A case series involving seven patients diagnosed with FHBL across three families.
  • Data collection included clinical, laboratory, imaging, and genetic information from medical records.
  • Genetic evaluation focused on identifying variants in genes associated with lipid metabolism, specifically *MTTP* and *APOB*.

Main Results:

  • The study identified FHBL in seven pediatric patients, with genetic analysis revealing *MTTP* variants in two siblings and *APOB* variants in five patients.
  • Patients presented with fatty liver, and some had elevated liver enzymes and abnormal lipid profiles (triglycerides, LDL, apolipoprotein B).
  • The mean BMI was 27 kg/m², with two patients classified as obese (BMI > 30 kg/m²).

Conclusions:

  • Familial hypobetalipoproteinemia (FHBL) should be considered in the differential diagnosis for pediatric fatty liver.
  • FHBL can coexist with other factors contributing to fatty liver, such as obesity.
Abstract

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...